CJC-1295 With DAC calculator
The long-acting form of CJC-1295, bound to a drug affinity complex that extends its half-life to about a week. Not approved; prohibited in sport.
Also known as: CJC-1295 DAC, Drug Affinity Complex CJC
FDA status — not an approved drug Not FDA-approved for any use. CJC-1295 was placed in Category 2 of FDA's bulk drug substances list. Prohibited in sport by WADA.
Schedule CJC-1295 With DAC → Set your dosing schedule and get a phone notification when each dose is due. Free.
What CJC-1295 With DAC is
CJC-1295 with DAC is the long-acting version of the GHRH analog. A drug affinity complex attached to the peptide binds albumin in the bloodstream, extending its half-life from hours to roughly a week. This produces sustained rather than pulsatile growth-hormone elevation, which is both its appeal and its main concern.
Research depth: 3/5 Small human pharmacokinetic studies showing sustained GH/IGF-1 elevation; development discontinued. Human trials: Small PK studies. This measures how much has been studied — counting animal and laboratory work — not whether it works for you.
How CJC-1295 With DAC works
It binds pituitary GHRH receptors to stimulate growth-hormone release, like the no-DAC form. The DAC addition causes it to circulate bound to albumin, so it keeps stimulating the pituitary continuously for days rather than in a short pulse. The result is a sustained rise in GH and IGF-1 that does not follow the body's natural pulsatile rhythm.
CJC-1295 With DAC side effects
Commonly reported
- Injection-site reactions
- Flushing and headache
- Water retention and joint aches
- Tingling or numbness in the hands
Serious — seek medical care
- Sustained, non-pulsatile GH and IGF-1 elevation raises insulin-resistance concern
- Development was discontinued after a safety event in one trial
- Prohibited in sport by WADA
This list is not exhaustive. Report anything unexpected to the clinician who prescribed it. If you have severe abdominal pain, trouble breathing, or signs of an allergic reaction, seek care the same day. See also our guide to peptide side effects by class.
A worked example
A 5 mg vial reconstituted with 2 mL of bacteriostatic water gives 2.5 mg/mL. A 2000 mcg dose is then 0.8 mL — about 80 units on a 100-unit insulin syringe, giving roughly 2 doses per vial before accounting for residual volume left in the vial and syringe.
Prefer paper? Download the printable CJC-1295 With DAC dosing chart (PDF) — every vial size and water volume in syringe units, with the same review byline as this page. All charts →
Commonly cited dose range
Figures circulating for CJC-1295 With DAC run from 1000 mcg to 4000 mcg. The DAC form is long-acting and dosed weekly rather than daily. Figures reflect community reference amounts in micrograms. There is no established or approved dose.
Read this as reference information, not instruction. These numbers describe what is commonly discussed, not what is right for any individual. Dose, frequency, and whether to use CJC-1295 With DAC at all are decisions for a licensed clinician who knows your history.
Common questions
What's the difference between CJC-1295 with and without DAC?
The DAC (drug affinity complex) version binds albumin in the blood, extending its half-life to roughly a week, so it is dosed weekly. The no-DAC form clears in hours and is dosed daily. Neither is approved.
Is the DAC form safe?
It produces sustained, non-pulsatile elevation of growth hormone and IGF-1, which differs from the body's natural pattern and raises concerns about insulin resistance and fluid retention. Development was discontinued after a safety event in one trial.